Anti-CD3 antibodies for type 1 diabetes: beyond expectations - PubMed (original) (raw)
Comment
. 2011 Aug 6;378(9790):459-60.
doi: 10.1016/S0140-6736(11)60980-X. Epub 2011 Jun 28.
Affiliations
- PMID: 21719098
- DOI: 10.1016/S0140-6736(11)60980-X
Comment
Anti-CD3 antibodies for type 1 diabetes: beyond expectations
Jean-François Bach. Lancet. 2011.
No abstract available
Comment on
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators. Sherry N, et al. Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28. Lancet. 2011. PMID: 21719095 Free PMC article. Clinical Trial.
Similar articles
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators. Sherry N, et al. Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28. Lancet. 2011. PMID: 21719095 Free PMC article. Clinical Trial. - [One step towards restoration of self-tolerance in human autoimmune diseases].
Chatenoud L. Chatenoud L. Med Sci (Paris). 2007 Feb;23(2):167-71. doi: 10.1051/medsci/2007232167. Med Sci (Paris). 2007. PMID: 17291426 Review. French. - The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic.
Chatenoud L. Chatenoud L. Handb Exp Pharmacol. 2008;(181):221-36. doi: 10.1007/978-3-540-73259-4_10. Handb Exp Pharmacol. 2008. PMID: 18071948 Review. - A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. Herold KC, et al. Diabetes. 2005 Jun;54(6):1763-9. doi: 10.2337/diabetes.54.6.1763. Diabetes. 2005. PMID: 15919798 Free PMC article. Clinical Trial. - [Anti-CD3 monoclonal antibodies: a new step towards therapy in new-onset type 1 diabetes].
Chatenoud L. Chatenoud L. Med Sci (Paris). 2006 Jan;22(1):5-6. doi: 10.1051/medsci/20062215. Med Sci (Paris). 2006. PMID: 16386207 French. No abstract available.
Cited by
- Therapy concepts in type 1 diabetes mellitus treatment: disease modifying versus curative approaches.
Lenzen S, Jörns A. Lenzen S, et al. J Mol Med (Berl). 2024 Oct 18. doi: 10.1007/s00109-024-02494-w. Online ahead of print. J Mol Med (Berl). 2024. PMID: 39420138 Review. - Increase in the Expression of Glucose Transporter 2 (GLUT2) on the Peripheral Blood Insulin-Producing Cells (PB-IPC) in Type 1 Diabetic Patients after Receiving Stem Cell Educator Therapy.
Zhao Y, Veysman B, Antolijao K, Zhao Y, Papagni Y, Wang H, Ross R, Tibbot T, Povrzenic D, Fox R. Zhao Y, et al. Int J Mol Sci. 2024 Jul 30;25(15):8337. doi: 10.3390/ijms25158337. Int J Mol Sci. 2024. PMID: 39125908 Free PMC article. - The immunology of type 1 diabetes.
Herold KC, Delong T, Perdigoto AL, Biru N, Brusko TM, Walker LSK. Herold KC, et al. Nat Rev Immunol. 2024 Jun;24(6):435-451. doi: 10.1038/s41577-023-00985-4. Epub 2024 Feb 2. Nat Rev Immunol. 2024. PMID: 38308004 Free PMC article. Review. - Immune Modulation of Platelet-Derived Mitochondria on Memory CD4+ T Cells in Humans.
Yu H, Hu W, Song X, Zhao Y. Yu H, et al. Int J Mol Sci. 2020 Aug 31;21(17):6295. doi: 10.3390/ijms21176295. Int J Mol Sci. 2020. PMID: 32878069 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical